A Phase 2 interventional study of Brief behavioral therapy and Zopiclone in Insomnia Chronic, sponsored by I.M. Sechenov First Moscow State Medical University. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-16.
Sponsored by I.M. Sechenov First Moscow State Medical University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background: Importance of chronic insomnia (CI) problem is determined by its high prevalence rate, comorbidity and resistance to the treatment. Although cognitive behavior treatment of insomnia (CBT-I) remains the recommended treatment for CI it has disadvantages of time consuming and low treatment response. Hence shortened and simplified behavioral approaches such as Brief Behavioral therapy of insomnia (BBT-I) are developed. The aim of the present study is to test the effectiveness of BBT-I program for chronic insomnia in comparison with zopiclone in Russian population. The anthropometric, psychological and polysomnographic characteristics of patients were measured to find predictors of effectiveness of each method.
Participants: 42 adults (14 males, 28 females, mean age 54 years) meeting the criteria for CI according International classification of sleep disorders-3 Methods: Participants were randomized into two groups. Each group passed 2-week courses of treatment by brief behavior treatment of insomnia (BBT-I) and zopiclone in different orders with 2-week washout period between the courses. Participants underwent in-lab polysomnography prior to the treatment and completed questionnaires (Insomnia Severity Index (ISI), Dysfunctional beliefs about sleep scale (DBAS), Beck Depression Inventory (BDI) and others) in the beginning and the end of each course
The study had a crossover design implying that every patient underwent two different treatment courses in random sequence: hypnotic or structured educational program (BBT-I) delivered in two sessions.
Each treatment course was separated by 2-weeks washout period that provided the opportunity to evaluate the sustainability of treatment effect.
Before and after each treatment course and after each washout period subjects completed set of questionnaires.
The total duration of the study was 8 weeks in which 6 visits including 1 night polysomnography (PSG), 2 face-to-face structured educational program sessions and 5 diagnostic interviews have been performed.
Participants A sample of 42 adults (14 males, 28 females, mean age 54 years from 29 to 80 years) meeting the criteria for chronic insomnia according ICSD-3 was recruited from outpatient care of Department of sleep medicine of University Hospital №3 of I.M. Sechenov First Moscow State Medical University. All participants were informed about the nature, purpose, risks, and discomforts that could arise from their participation, and about their right to withdraw at any time. Subjects documented their willingness to participate by signing the informed consent form, approved by local Ethic Committee.
Treatment methods. BBT-I program includes two weekly one hour individual sessions; Hypnotic (zopiclone) in a dose of 7,5 mg has to be taken 30 minutes before bedtime for two weeks
Measures Questionnaires. During the first visit patients underwent structured clinical interview and filled in self-report questionnaires: Beck Depression Inventory (BDI), State-trait anxiety inventory (STAI), Toronto Alexithymia Scale - short version (TAS-20) , Big Five Questionnaire (BFQ-2R), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Dysfunctional beliefs about sleep scale (DBAS), Sleep hygiene index (SHI).
During the next 4 visits participants repeatedly underwent diagnostic tests included BDI, STAI, PSQI, ISI, DBAS, SHI.
Participants kept daily sleep diaries where they recorded bedtime and morning rise time, sleep onset latency (SOL), number of night awakenings and time of wakefulness after sleep onset before waking up (WASO) for the whole study period.
On the last visit participants completed questionnaire for assessment of effectiveness of treatment along with diagnostic routine. Patients were asked to rank the effectiveness of proposed methods of treatment (didactic presentation, stimulus control, sleep restriction, relaxing recording and zopiclone) in ascending order from 1 to 5 points (5 seems most effective).
Polysomnography. Participants underwent in-lab PSG (1 night without adaptation night) prior to the treatment in order to exclude other disorders producing subjective sleep complaints (sleep apnea, periodic limb movements disorder). Standard polysomnography montage including 6 monopolar electroencephalography (EEG) channels; 1 submental electromyogram (EMG) channel; 2 electrooculogram (EOG) channels; 2 EMG channels of the right and left tibialis anterior muscles; 1 electrocardiogram channel; oronasal airflow pressure; thoracic and abdominal efforts; respiratory sound; oxygen saturation; body position with videomonitoring was performed. The objective sleep measures included total sleep time (TST), sleep-onset latency, wake time after sleep onset (WASO), number of awakenings, sleep efficiency (the ratio of TST to time spent in bed multiplied on 100%, SE), percentage of sleep stages. PSG data were analysed according the 2007 American Academy of Sleep Medicine criteria including its revision in 2012.
2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.
This study's enrollment of 42 is below the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Browse Sleep Initiation and Maintenance Disorders studies →I.M. Sechenov First Moscow State Medical University is the lead sponsor of 137 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
meeting the criteria for chronic insomnia according ICSD-3 willingness to take part in the study and signed form
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
Behavioral: Brief behavioral therapy · Drug: Zopiclone
received two-week brief behavioral therapy followed by medication therapy (zopiclone).
Behavioral: Brief behavioral therapy · Drug: Zopiclone
program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording "Relaxation and refreshment session for insomnia" created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off.
Also known as: BBT-I
zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
Also known as: hypnotic
Insomnia Severity Index
self reported insomnia symptoms severity by Insomnia severity index . Each item is scored 0 (no problem) - 4 (very big problem) with total between 0-28 (absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
Time frame: For BBT-I-first group: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/Month 1); For zopiclone-first group: after washout period (Day 28/Week 4/Month 1) after second treatment course (Day 42/Week 6/Month 2)
Beck Depression Inventory
21-item questionnaire assessing (on 4-point Likert scales) the intensity of depressive symptoms in the past week. Minimum score 0, maximum score 63 points. Higher total score represents more severe depressive symptoms
Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
State Anxiety Subscale (STAI)
State trait anxiety scale is a 2-part questionnaire assessing state (situational) and trait anxiety. State anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms
Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Dysfunctional Beliefs About Sleep Scale
questionnaire assessing sleep related cognitions in 16 item rated on a 10-point Likert scale. Minimum score is 0, maximum score is 160 points. Higher total score represents more intensive disfunctional beliefs
Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Sleep Hygiene Index
questionnaire assessing sleep related behavior in 13 item rated on a 5-point Likert scale.Minimum score 13 points and maximum score 65 points. Higher total score represents worse sleep hygiene
Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Pittsburgh Sleep Quality Index
19-item questionnaire evaluating sleep quality over the past month. The first 4 items are open questions, items 5 to 19 are rated on a 4-point Likert scale. A total score range from 0 to 21. A score \> 5 suggests poor sleep quality.
Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Trait Anxiety Subscale (STAI)
STAI is a 2-part questionnaire assessing state (situational) and trait anxiety. Trait anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for each subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms
Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Toronto Alexithymia Scale (TAS-20)
Degree of alexithymia evaluated by Toronto Alexithymia scale (20 questions) Measure Description: 0-100 scores. higher values represent worse outcome
Time frame: once at baseline assessment
Sleep Latency
time period from bedding to sleep onset
Time frame: once at baseline assessment
Total Sleep Time
total sleep episode minus wake time
Time frame: once at baseline assessment
Sleep Efficiency
Prercentage of Total Bed Time
Time frame: once at baseline assessment
Wake After Sleep Onset
total duration of all periods of wakefulness between sleep onset and final awakening in the morning
Time frame: once at baseline assessment
Amount of Awakenings
Number of awakenings between sleep onset and final morning awakening
Time frame: once at baseline assessment
N1 NREM Sleep Percentage
Percentage of Total Sleep Time
Time frame: once at baseline assessment
N2 NREM Sleep Percentage
Percentage of Total Sleep Time
Time frame: once at baseline assessment
N3 NREM Sleep Percentage
Percentage of Total Sleep Time
Time frame: once at baseline assessment
REM Sleep Percentage
Percentage of Total Sleep Time
Time frame: once at baseline assessment
| Milestone | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Started | 19 | 23 |
| Completed | 18 | 23 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Started | 18 | 23 |
| Completed | 18 | 23 |
| Not completed | 0 | 0 |
| Milestone | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Started | 18 | 23 |
| Completed | 18 | 21 |
| Not completed | 0 | 2 |
| Withdrew: Unrelated acute exacerbation | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Started | 18 | 21 |
| Completed | 12 | 18 |
| Not completed | 6 | 3 |
| Withdrew: Physician decision | 6 | 3 |
self reported insomnia symptoms severity by Insomnia severity index . Each item is scored 0 (no problem) - 4 (very big problem) with total between 0-28 (absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 18.6 ± 5.2 | 18.9 ± 3.9 |
| First treatment course | 13.1 ± 5.2 | 14.0 ± 5.7 |
| After washout | 14.3 ± 6.3 | 16.1 ± 4.7 |
| Second treatment course | 12.1 ± 6.1 | 12.8 ± 5.4 |
| After follow-up | 13.1 ± 4.7 | 12.7 ± 5.9 |
21-item questionnaire assessing (on 4-point Likert scales) the intensity of depressive symptoms in the past week. Minimum score 0, maximum score 63 points. Higher total score represents more severe depressive symptoms
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 11.5 ± 6.8 | 9.3 ± 7.3 |
| first treatment course | 8.4 ± 6.8 | 9.4 ± 8.2 |
| After washout | 8.4 ± 8.2 | 9.8 ± 5.1 |
| Second treatment course | 9.2 ± 9.0 | 8.5 ± 6.2 |
| After follow-up | 9.0 ± 8.1 | 7.4 ± 6.2 |
State trait anxiety scale is a 2-part questionnaire assessing state (situational) and trait anxiety. State anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 45.1 ± 8.8 | 43.2 ± 8.5 |
| First treatment course | 43.8 ± 8.6 | 44.3 ± 9.1 |
| After washout | 45.5 ± 9.0 | 44.5 ± 9.8 |
| Second treatment course | 45.1 ± 9.1 | 44.0 ± 9.6 |
| After follow-up | 46.9 ± 6.5 | 44.2 ± 10.4 |
questionnaire assessing sleep related cognitions in 16 item rated on a 10-point Likert scale. Minimum score is 0, maximum score is 160 points. Higher total score represents more intensive disfunctional beliefs
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 105.2 ± 29.0 | 93.2 ± 35.0 |
| First treatment course | 83.8 ± 34.8 | 96.4 ± 36.4 |
| After washout | 84.76 ± 36.9 | 103.6 ± 32.2 |
| Second treatment course | 84.5 ± 39.8 | 89.2 ± 35.4 |
| After follow-up | 62.8 ± 34.5 | 92.0 ± 34.5 |
questionnaire assessing sleep related behavior in 13 item rated on a 5-point Likert scale.Minimum score 13 points and maximum score 65 points. Higher total score represents worse sleep hygiene
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 26.8 ± 7.4 | 25.2 ± 5.9 |
| First treatment course | 24.0 ± 5.6 | 25.0 ± 6.9 |
| After washout | 24.7 ± 6.0 | 25.5 ± 7.4 |
| Second treatment course | 24.7 ± 6.6 | 24.3 ± 6.6 |
| After follow-up | 23.8 ± 6.5 | 25.2 ± 7.6 |
19-item questionnaire evaluating sleep quality over the past month. The first 4 items are open questions, items 5 to 19 are rated on a 4-point Likert scale. A total score range from 0 to 21. A score \> 5 suggests poor sleep quality.
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 13.4 ± 3.6 | 11.9 ± 4.1 |
| First treatment course | 10.5 ± 4.5 | 11.3 ± 4.1 |
| After washout | 11.3 ± 4.4 | 12.7 ± 3.8 |
| Second treatment course | 10.8 ± 4.4 | 11.7 ± 4.8 |
| After follow-up | 11.2 ± 4.9 | 11.1 ± 4.7 |
STAI is a 2-part questionnaire assessing state (situational) and trait anxiety. Trait anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for each subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms
| units on a scale | BBT-I First Group | Zopiclone First Group |
|---|---|---|
| Baseline/initial examination | 48.7 ± 6.9 | 48.3 ± 8.1 |
| First treatment course | 48.3 ± 8.1 | 48.3 ± 8.6 |
| After washout | 48.6 ± 7.6 | 49.3 ± 7.0 |
| Second treatment course | 46.3 ± 9.5 | 48.5 ± 8.3 |
| After follow-up | 46.3 ± 8.6 | 48.8 ± 10.7 |
Degree of alexithymia evaluated by Toronto Alexithymia scale (20 questions) Measure Description: 0-100 scores. higher values represent worse outcome
| scores on a scale | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Toronto Alexithymia Scale (TAS-20) | 49.83 ± 15.9 | 49.33 ± 10.0 |
time period from bedding to sleep onset
| minutes | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Sleep Latency | 38.53 ± 21.7 | 54.5 ± 51.0 |
total sleep episode minus wake time
| hours | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Total Sleep Time | 5.72 ± 1.6 | 5.51 ± 1.6 |
Prercentage of Total Bed Time
| percentage of polysomnogram time | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Sleep Efficiency | 64.68 ± 17.9 | 63.29 ± 18.0 |
total duration of all periods of wakefulness between sleep onset and final awakening in the morning
| minutes | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Wake After Sleep Onset | 102.39 ± 69.0 | 104.75 ± 76.1 |
Number of awakenings between sleep onset and final morning awakening
| awakenings | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| Amount of Awakenings | 13.78 ± 6.1 | 13.25 ± 6.9 |
Percentage of Total Sleep Time
| percentage of total sleep time | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| N1 NREM Sleep Percentage | 4.16 ± 3.1 | 3.70 ± 3.3 |
Percentage of Total Sleep Time
| percentage of time | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| N2 NREM Sleep Percentage | 64.19 ± 10.2 | 62.58 ± 8.4 |
Percentage of Total Sleep Time
| percentage of total sleep time | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| N3 NREM Sleep Percentage | 17.52 ± 8.8 | 16.39 ± 7.0 |
Percentage of Total Sleep Time
| percentage of total sleep time | Zopiclone First, Then BBT-I | BBT-I First, Then Zopiclone |
|---|---|---|
| REM Sleep Percentage | 14.1 ± 5.5 | 17.0 ± 7.7 |
Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BBT-I | 0/42 (0%) | 0/42 (0%) | 0/42 (0%) |
| Zopiclone | 0/41 (0%) | 0/41 (0%) | 2/41 (4.9%) |
| Event | BBT-I | Zopiclone |
|---|---|---|
| rash hypersensitivity reaction to zopicloneSkin and subcutaneous tissue disorders | 0/42 | 1/41 |
| bitter tasteHepatobiliary disorders | 0/42 | 1/41 |
| Age, Categorical(Participants) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 20 | 33 |
| >=65 years | 6 | 3 | 9 |
| Age, Continuous(years) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Mean | 55.0 ± 14.8 | 47.5 ± 14.1 | 50.7 ± 14.5 |
| Sex: Female, Male(Participants) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Female | 11 | 16 | 27 |
| Male | 8 | 7 | 15 |
| Race and Ethnicity Not Collected(Participants) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Russia | 19 | 23 | 42 |
| Beck depression inventory(units on a scale) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Mean | 10.8 ± 5.0 | 12.8 ± 7.2 | 12.1 ± 6.1 |
| State anxiety inventory(units on a scale) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Mean | 43.5 ± 8.7 | 46.9 ± 6.9 | 45.3 ± 8.1 |
| trait anxiety inventory(units on a scale) | Zopiclone First Group | BBT-I First Group | Total |
|---|---|---|---|
| Mean | 49.6 ± 8.3 | 49.1 ± 7.2 | 49.3 ± 7.5 |
14 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Since our lab has no plans to continue or extend the registered study we are not planning share individual patient data with other researches
Ran from Apr 2015 to primary completion in Mar 2017, 23 months.
Results were first posted in Jun 2019, 2 years 3 months after primary completion.
Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 23 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zopiclone
Sleep Initiation and Maintenance Disorders →
I.M. Sechenov First Moscow State Medical University →